Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir
{"title":"激素受体阳性乳腺癌新辅助内分泌治疗时间及对浸润性肿瘤细胞的影响。","authors":"Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir","doi":"10.1007/s10549-025-07722-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.</p><p><strong>Methods: </strong>A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.</p><p><strong>Results: </strong>104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.</p><p><strong>Conclusion: </strong>Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.\",\"authors\":\"Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir\",\"doi\":\"10.1007/s10549-025-07722-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.</p><p><strong>Methods: </strong>A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.</p><p><strong>Results: </strong>104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.</p><p><strong>Conclusion: </strong>Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.</p>\",\"PeriodicalId\":9133,\"journal\":{\"name\":\"Breast Cancer Research and Treatment\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10549-025-07722-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07722-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.
Purpose: Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.
Methods: A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.
Results: 104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.
Conclusion: Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.
期刊介绍:
Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.